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Abstract 
Introduction 
Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic 
stroke. The risk of a recurrent ischemic stroke is high. This prospective single center study 
was to assess whether the repeated rtPA-treatment is beneficial for acute stroke patients or 
not. 
Methods 
All thrombolysed patients’ data at the Department of Neurology, University of Debrecen have 
been recorded in the Debrecen Thrombolysis Database (DTD) since 2004. We identified 21 
patients with repeated thrombolysis. Stroke severity by the NIH stroke scale score (NIHSSS) 
and imaging findings by the ASPECT score were evaluated on admission and one day later. 
The modified Rankin Scale (mRS) at 3 months and case fatality at one year were evaluated. 
Comparing first and second thrombolyses, we screened for bleeding and allergic reactions to 
determine safety.  
Results 
Within the 27-month median time, 18 patients were thrombolysed twice, with complete 
follow-up. In recurrent stroke patients diabetes mellitus, congestive heart failure and 
anticoagulation were more common. Admission cholesterol levels were also decreased. After 
the first and second treatments, 24-hour-NIHSSS were 3 (1;6) and 7 (1;10), respectively. At 
three months, good outcome was significantly higher after the first treatment than those of 
DTD, with no differences between two attempts. There was little difference in three-month 
and one-year outcomes, regardless of laterality – ipsilateral or contralateral hemisphere – in 
recurrent strokes. One patient had non-symptomatic intracranial bleeding after repeated rtPA-
treatment. 
Discussion 
Recurrent rtPA treatment may be safe and effective in patients who have mild or moderate 
residual symptoms after the index stroke. 
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Introduction 
Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic 
stroke [1, 2, 3, 4, 5]. Nevertheless it has been an established fact that the risk of a recurrent 
ischemic stroke is high, especially within five years. Death and severe disability are more 
probable in case of a recurrent stroke. However, different publications have reported 
development of antibodies against the recombinant protein in animal models [6;7] and 
humans alike [8, 9, 10]. These facts raise the question of allergy to rtPA and the neutralizing 
antibodies against the rtPA, at the second attempt, possibly influencing the treatment 
unfavourably [10].  
The aim of this study was to assess whether repeated rtPA treatment is beneficial for recurrent 
acute ischemic stroke patients or not (because of possible desensitization). We were interested 
whether there are more side effects (e.g. allergic reaction, haemorrhage) by the second 
attempt than by the primary treatment. 
 
Methods 
Subjects 
Started on 1st January 2004, the Thrombolysis Database includes all thrombolysed patients’ 
data from the Department of Neurology, University of Debrecen with a catchment area of 
approximately 600,000 inhabitants and 600-700 acute stroke hospitalizations per year. The 
time window from symptom onset was three hours for intravenous (IV) treatment until 
October 2008, and 4.5 hours afterwards. The Regional Research Ethics Committee of the 
University of Debrecen approved intra-arterial (IA) use of rtPA with a 6-hour time-window. 
Altogether we identified 21 patients who had undergone repeated thrombolysis. Three of 
those did not complete follow up but the 18 patients who did, were enrolled in the study. 
They were divided into three groups as follows: first thrombolysed (I.), second thrombolysed 
(II.), and both groups were compared with a pooled group of all patients in the Debrecen 
Thrombolysis Database (DTD all) of 369 patients. The DTD was chosen for comparison since 
it was a well-defined homogenous group [11]. 
Database 
We created a database recording details such as age, gender, time of stroke onset, time of 
arrival in the hospital, time of the CT scan result, time of administering  rtPA, previous 
medical history (hypertension, diabetes mellitus, atrial fibrillation, heart failure, self reported 
smoking and alcohol consumption habits), on-admission stroke severity (including the 
National Institute of Health Stroke Scale Score - NIHSSS) [12], prestroke modified Rankin 
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Scale score (mRS) [13, 14], systolic and diastolic blood pressure before the initiation of rtPA 
administration, serum glucose level, INR, APTT, cholesterol, triglyceride, on-admission 
CT/CTA scan, and, if performed, digital subtraction angiography, and a follow-up (24 hours ± 
2 hours) CT scan. We registered the NIHSS Score at 24 hours, medications for secondary 
prevention, mRS at three months, and survival status at one year. The study was approved by 
the Regional Research Ethics Committee of the University of Debrecen. 
Imaging 
Non-contrast computed tomography (CT) was performed on admission. Arterial occlusion 
(trunk or at least one branch of any large artery) was identified by CTA. CT was repeated one 
day after treatment and in case of clinical deterioration. The Alberta Stroke Programme Early 
CT Score (ASPECTS) was determined unblinded to patient characteristics and was stratified 
to ≤7 (Group I-severe) and above 7 (Group II-mild) [15, 16]. Hemorrhagic infarction (HI) or 
parenchymal hematoma (PH) was defined according to the European Cooperative Acute 
Stroke Study [17, 18]. We used three definitions for symptomatic intracerebral hemorrhage 
(SICH): the SITS, ECASS and NINDS criteria [1, 17, 19]. 
Treatment 
IV treatment was administered according to the EUSI and ESO guidelines of 2003 and 2008, 
respectively [20, 21]. Among the twice thrombolysed patients one underwent IA treatment, 
and he received a total of 30mg rtPA until opening of the artery. IA use of rtPA was approved 
by the Regional Research Ethics Committee of the University of Debrecen. 
Outcomes 
The NIHSSS and case fatality were evaluated the day after admission. Outcome assessment 
was performed using mRS at three months and outcomes were dichotomized into favourable 
(mRS 0-2) and unfavourable (mRS>2 points) [22]. Survival status was evaluated at one year. 
Statistical analysis 
Statistical analysis was carried out using the SPSS for Windows 19.0 (SPSS Inc. Chicago, 
USA). The categorical variables were assessed with Pearson χ2 test. 
Significant differences were considered if p<0.05. 
Results 
Prestroke characteristics 
The median time between two thrombolytic therapies was 27 months (5-67). Among the 
patients receiving treatment 55.5 % were males. The prevalence of hypertension was similar 
in all of the groups. Prestroke diabetes mellitus was more common in case of recurrent 
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therapy (Group II) than at the first attempt (Group I) (p=0.087) or in the DTD group (p<0.05). 
Prestroke congestive heart failure was slightly but not significantly increased in Group II (p= 
0.423). Prestroke anticoagulation was significantly higher (p<0.05) in group II than in Group I 
or DTD (p<0.05). Of course, all of the patients in Group II had a history of stroke (Table 1). 
On admission, cholesterol levels were  much lower in Group II, compared with Group I and 
Group DTD (p<0.05). Triglyceride levels were in the normal range in all groups.  
Treatment characteristics 
There was no significant difference in the onset to treatment time between the two attempts 
(140 minutes group I and 136 minutes Group II) (Figure 1). 
Based on systolic and diastolic blood pressure, there was no significant difference among the 
groups. Blood sugar levels before treatment were also similar in all groups. 
The severity of stroke on admission was similar in both attempts on admission: first treatment 
9 (7;13), second treatment: 9 (6;14) (Table 1). The median 24-hour-NIHSSS was 3 (1;6) after 
the first treatment, and 7 (1;10) after the recurrent rtPA treatment. After the first thrombolysis 
the 24-hour improvement was better than after the repeated treatment (2 points). 
Outcome 
Progression could be detected in recurrent stroke compared to the status after the first 
treatment. The improvement after the recurrent stroke was smaller in NIHSSS at 24 hours, 
than after the index stroke. The median 24-hour-NIHSSS was 3 (1;6) after the first treatment 
and 7 (1;10) after the recurrent rtPA treatment. 
The outcome at 24 hours was significantly better after the first treatment than after second 
thrombolysis (p<0.05) or in all DTD group (p<0.05) Even the second treatment had a 
significant benefit compared with the DTD group (p< 0.05) (Table 1). 
We characterized   new ischemic lesions using ASPECT Score. At 24 hours, the average 
ASPECT score was 10 for Group I and 9 for Group II, i.e. 9 and 8 points, respectively. 
Comparing the groups in the study it can be stated, that ASPECTS at 24 hours at the first 
treatment was better, but it was still very good even if it was compared with DTD all (Figure 
2). 
At three months, favourable outcomes scored higher, i.e. poor outcomes and deaths were 
significantly lower in both Group I, Group II than in DTD all (p <0.05 I.-DTD; p=0.068 II.-
DTD) However, there  was no difference  between Groups I and II (p=0.338) (Figure 3). 
After the first rtPA, all patients were alive at one year as expected but after the second one, 
three patients were dead at one year (27.7%). At one year there was a significant difference 
7 
 
between the outcome of first thrombolysis and the DTD group (p<0.05); but the other 
comparisons were not significant (II.-DTD p=0.311; I.-II. p= 0.07). 
Outcome at three months and at one year did not differ significantly if the recurrent stroke 
affected the ipsilateral or contralateral hemisphere (Figure 4).  
Safety data 
Among the patients with complete follow up, no haemorrhagic transformation, SICH 
(symptomatic intracerebral hemorrhage) was detected either after the index rtPA treatment or 
after recurrent thrombolysis. However, one patient whose follow up was not completed had a 
haemorrhagic transformation (not SICH). Minor bleeding (subconjunctival, gingival and 
tongue bleeding), occurred after the second thrombolysis in four cases but there was no need 
to interrupt their treatment. No allergic reaction or angioneurotic edema occurred. 
At three months, mortality rates in Group II and DTD all were 11.1% and 22.8%, while at one 
year the relevant data were found at 27.7% and 35.5%, respectively (Figure 3). 
 
Discussion 
Unfavourable outcome (disability and death) increases in case of recurrent stroke [23]. 
Despite its beneficial effect, recurrent thrombolysis has been reported in only few publications 
[23, 24]. 
The patients in the study had several risk factors such as diabetes mellitus, atrial fibrillation, 
congestive heart failure, and, of course, stroke when rethrombolysed. Nevertheless we 
assume, that many of these risk factors did not appear as new, but had been there silently and 
undiscovered prior to the first stroke. This study was not designed to prove this assumption, 
since further research is required to verify this theory. However, it must be highlighted that 
significantly lower cholesterol levels show the importance of secondary stroke prevention 
(statin therapy). The fact that systolic blood pressure exceeded 140 mmHg even in the group 
with recurrent stroke shows the shortcomings of care. 
Although all patients were aware of the symptoms of stroke at the second time, they did not 
arrive at our department earlier. The median door-to-needle time was within the 60 minutes’ 
golden hour as advised in the latest guidelines [25]. 
Most patients after the index stroke had mild symptoms, but at the onset of recurrent stroke, 
patients had moderate symptoms. In recurrent stroke, the ASPECTS status at 24 hours was 
worse compared to that in the first treatment. 
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Contrary to our expectations the outcome was similar if the stroke appeared either in the 
ipsilateral or in the contralateral hemisphere. Of course, this can also be attributed to small 
sample size. 
Death ratio was similar to those thrombolysed only once even after the recurrent rtPA 
treatment. The outcome at 24 hours and at three months was worse after the second 
thrombolysis, but the number of previous diseases was higher. Only one patient had non- 
symptomatic intracranial bleeding after the second rtPA treatment. Low rate of intracranial 
bleeding could be due to careful patient selection. With recruiting patients with more severe 
neurological symptoms and ASPECTS the bleeding ratio would probably be higher. Repeated 
thrombolysis among our patients was also safe. 
Our study has several limitations. The number of the patients with repeated thrombolysis is 
small, and our study is possibly underpowered to draw conclusions regarding effectiveness 
and safety. By examining our data of twice thrombolysed patients, we found that they had 
mild or moderate symptoms after the first thrombolysis. Despite the above, this study might 
have its value. Similarly to our data all publications in this field include a small sample, 
showing the rarity of recurrent treatment [23]. The advantage of this study may be that all 21 
patients were treated and controlled after stroke at the same department. 
  
Conclusion 
Although drawing conclusions has its limitations we think that recurrent rtPA treatment may 
be safe and effective in patients who have mild or moderate residual symptoms after the index 
stroke. Definitely, a study of a larger sample size is necessary to allow for further conclusions. 
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Figure legends 
Table 1 Prestroke parameters and basic parameters of the rtPA treatment 
Figure 1 Logistic data. Onset to treatment time by I. rtPA treatment (median) 140 min, II. 
rtPA treatment (median) 136 min 
Figure 2 ASPECTS at 24 hours. /p =0.027 I.-DTD; p=0.012 II.-DTD;I.-II./ 
Figure 3 Outcome at 3 months (A) /p =0.009 I.-DTD; p=0.068 II.-DTD; I.-II. p=0.338/ and at 
one year (B) /p =0.008 I.-DTD; p=0.311 II.-DTD; I.-II. p= 0.07/ 
Figure 4 Outcome at 3 months (modified Rankin Scale Score) and at one year (case fatality) 
after recurrent thrombolysis depending on whether the recurrent stroke affected the ipsilateral 
or contralateral hemispheres 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
